{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T21:20:26Z","timestamp":1778275226879,"version":"3.51.4"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,21]]},"DOI":"10.7759\/cureus.105591","type":"journal-article","created":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T13:03:30Z","timestamp":1774098210000},"source":"Crossref","is-referenced-by-count":1,"title":["Semaglutide-Associated Acute Pancreatitis in a Patient With Type 2 Diabetes Mellitus: A Case Report"],"prefix":"10.7759","author":[{"given":"Piyush","family":"Puri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Akhavan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Shadan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tzipora","family":"Levitt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aakash A","family":"Soni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso SP","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, et al.. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016, 375:1834-44. 10.1056\/NEJMoa1607141","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2013.2720","article-title":"Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study","volume":"173","author":"Singh S","year":"2013","unstructured":"Singh S, Chang HY, Richards TM, Weiner JP, Clark JM, Segal JB. Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. JAMA Intern Med. 2013, 173:534-9. 10.1001\/jamainternmed.2013.2720","journal-title":"JAMA Intern Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.69704","article-title":"Semaglutide-induced acute pancreatitis leading to death after four years of use","volume":"16","author":"Dagher C","year":"2024","unstructured":"Dagher C, Jailani M, Akiki M, Siddique T, Saleh Z, Nadler E. Semaglutide-induced acute pancreatitis leading to death after four years of use. Cureus. 2024, 16:e69704. 10.7759\/cureus.69704","journal-title":"Cureus"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.69844","article-title":"Acute pancreatitis likely due to semaglutide","volume":"16","author":"Hughes K","year":"2024","unstructured":"Hughes K, Sumaruth YR, Mohammed E, Sant Bakshsingh V. Acute pancreatitis likely due to semaglutide. Cureus. 2024, 16:e69844. 10.7759\/cureus.69844","journal-title":"Cureus"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.43773","article-title":"Acute pancreatitis in a patient taking semaglutide","volume":"15","author":"Patel F","year":"2023","unstructured":"Patel F, Gan A, Chang K, Vega KJ. Acute pancreatitis in a patient taking semaglutide. Cureus. 2023, 15:e43773. 10.7759\/cureus.43773","journal-title":"Cureus"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14030944","article-title":"Pancreatitis risk associated with GLP-1 receptor agonists, considered as a single class, in a comorbidity-free subgroup of type 2 diabetes patients in the United States: a propensity score-matched analysis","volume":"14","author":"Ayoub M","year":"2025","unstructured":"Ayoub M, Chela H, Amin N, Hunter R, Anwar J, Tahan V, Daglilar E. Pancreatitis risk associated with GLP-1 receptor agonists, considered as a single class, in a comorbidity-free subgroup of type 2 diabetes patients in the United States: a propensity score-matched analysis. J Clin Med. 2025, 14:944. 10.3390\/jcm14030944","journal-title":"J Clin Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s40200-024-01552-x","article-title":"Dose-dependent pancreatitis risk associated with GLP-1 agonists","volume":"24","author":"Gu JH","year":"2025","unstructured":"Gu JH, Samarneh M. Dose-dependent pancreatitis risk associated with GLP-1 agonists. J Diabetes Metab Disord. 2025, 24:33. 10.1007\/s40200-024-01552-x","journal-title":"J Diabetes Metab Disord"},{"key":"ref8","article-title":"Glucagon-like peptide-1 receptor agonists","author":"Collins L","year":"2024","unstructured":"Collins L, Costello RA. Glucagon-like peptide-1 receptor agonists. StatPearls. StatPearls Publishing, Treasure Island (FL); 2024."},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding JP","year":"2021","unstructured":"Wilding JP, Batterham RL, Calanna S, et al.. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021, 384:989-1002. 10.1056\/NEJMoa2032183","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.2337\/dci22-0027","article-title":"Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO)","volume":"45","author":"de Boer IH","year":"2022","unstructured":"de Boer IH, Khunti K, Sadusky T, et al.. Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care. 2022, 45:3075-90. 10.2337\/dci22-0027","journal-title":"Diabetes Care"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.2337\/dc25-S009","article-title":"Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2025","volume":"48","year":"2025","unstructured":"Pharmacologic approaches to glycemic treatment. standards of care in diabetes-2025. Diabetes Care. 2025, 48:S181-206. 10.2337\/dc25-S009","journal-title":"Diabetes Care"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.14744\/etd.2020.03442","article-title":"Effects of Ramadan fasting on gastrointestinal system","volume":"43","author":"Payza U","year":"2021","unstructured":"Payza U, Kayal\u0131 A, Karakaya Z, et al.. Effects of Ramadan fasting on gastrointestinal system. J Clin Pract Res. 2021, 43:350-4. 10.14744\/etd.2020.03442","journal-title":"J Clin Pract Res"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/448393-semaglutide-associated-acute-pancreatitis-in-a-patient-with-type-2-diabetes-mellitus-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T13:03:31Z","timestamp":1774098211000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/448393-semaglutide-associated-acute-pancreatitis-in-a-patient-with-type-2-diabetes-mellitus-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,21]]},"references-count":12,"URL":"https:\/\/doi.org\/10.7759\/cureus.105591","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,21]]}}}